SynthesisEuropean journal of clinical pharmacology2015

Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.

Ying Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.